drugset / Trial / NCT06358053
CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers
NaSingle-groupOpen-labelTreatment
Summary
A single center, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in HLA-A\*02:01+ Subjects HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine RP2D of CRTE7A2-01 TCR-T cell injection.
Timeline
- Start
- 2024-04-15
- Primary completion
- 2027-12-31
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRTE7A2-01 | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | aldesleukin | Protein / enzyme biologic | — | — |